Summary of Study ST003044
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001875. The data can be accessed directly via it's Project DOI: 10.21228/M8BX4T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST003044 |
Study Title | A High-Fat Eucaloric Diet Induces Reprometabolic Syndrome of Obesity in Normal Weight Women - lipidomics |
Study Summary | Lipidomics analysis was performed on plasma from human female subjects before, during, and after a high fat diet. |
Institute | University of Colorado Denver |
Last Name | Haines |
First Name | Julie |
Address | 12801 E 17th Ave, Room 1303, Aurora, Colorado, 80045, USA |
julie.haines@cuanschutz.edu | |
Phone | 3037243339 |
Submit Date | 2023-12-15 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2024-02-05 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001875 |
Project DOI: | doi: 10.21228/M8BX4T |
Project Title: | A High-Fat Eucaloric Diet Induces Reprometabolic Syndrome of Obesity in Normal Weight Women |
Project Summary: | Objective: We examined the effects of one month of a eucaloric, high-fat (48% of calories) diet (HFD) on gonadotropin secretion in normal weight women to interrogate the role of free fatty acids and insulin in mediating the relative hypogonadotropic hypogonadism of obesity. Methods: Eighteen eumenorrheic women (BMI 18-25 kg/m2) were studied in the early follicular phase of the menstrual cycle before and after exposure to a HFD with frequent blood sampling for LH and FSH, followed by an assessment of pituitary sensitivity to GnRH. Mass spectrometrybased plasma metabolomic analysis was also performed. Paired testing and time series analysis were performed as appropriate. Results: Mean endogenous LH (unstimulated) was significantly decreased after the HFD (4.3 ±1.0 vs 3.8 ± 1.0, P<0.01); mean unstimulated FSH was not changed. Both LH (10.1 ± 1.0 vs 7.2 ± 1.0, P<0.01), and FSH (9.5 ± 1.0 vs 8.8 ± 1.0, P<0.01) response to 75 ng/kg of GnRH were reduced after the HFD. Mean LH pulse amplitude and LH interpulse interval were unaffected by the dietary exposure. Eucaloric HFD exposure did not cause weight change. Plasma metabolomics confirmed adherence with elevation of fasting free fatty acids (especially long-chain mono-, poly- and highly-unsaturated fatty acids) by the last day of the HFD. Conclusion: One-month exposure to a HFD successfully induced key reproductive and metabolic features of Reprometabolic Syndrome in normal weight women. Dietary factors may underly the gonadotrope compromise seen in obesity related subfertility and that therapeutic dietary interventions, independent of weight loss, may be possible. |
Institute: | University of Colorado Denver |
Laboratory: | Lab of Angelo D'Alessandro in collaboration with lab of Nanette Santoro |
Last Name: | Haines |
First Name: | Julie |
Address: | 12801 E 17th Ave, Room 1303, Aurora, Colorado, 80045, USA |
Email: | julie.haines@cuanschutz.edu |
Phone: | 3037243339 |
Subject:
Subject ID: | SU003159 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Gender: | Female |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Factor |
---|---|---|
SA330443 | DS1-28-49 | On-diet |
SA330444 | DS1-28-02 | On-diet |
SA330445 | DS1-28-43 | On-diet |
SA330446 | DS1-28-41 | On-diet |
SA330447 | DS1-28-52 | On-diet |
SA330448 | DS1-28-56 | On-diet |
SA330449 | DS1-28-54 | On-diet |
SA330450 | DS1-28-38 | On-diet |
SA330451 | DS1-28-46 | On-diet |
SA330452 | DS1-28-11 | On-diet |
SA330453 | DS1-28-35 | On-diet |
SA330454 | DS1-28-05 | On-diet |
SA330455 | DS1-28-14 | On-diet |
SA330456 | DS1-28-08 | On-diet |
SA330457 | DS1-28-17 | On-diet |
SA330458 | DS1-28-26 | On-diet |
SA330459 | DS1-28-29 | On-diet |
SA330460 | DS1-28-20 | On-diet |
SA330461 | DS1-28-36 | Post-diet |
SA330462 | DS1-28-30 | Post-diet |
SA330463 | DS1-28-39 | Post-diet |
SA330464 | DS1-28-50 | Post-diet |
SA330465 | DS1-28-47 | Post-diet |
SA330466 | DS1-28-44 | Post-diet |
SA330467 | DS1-28-27 | Post-diet |
SA330468 | DS1-28-03 | Post-diet |
SA330469 | DS1-28-21 | Post-diet |
SA330470 | DS1-28-06 | Post-diet |
SA330471 | DS1-28-09 | Post-diet |
SA330472 | DS1-28-18 | Post-diet |
SA330473 | DS1-28-15 | Post-diet |
SA330474 | DS1-28-12 | Post-diet |
SA330475 | DS1-28-45 | Pre-diet |
SA330476 | DS1-28-42 | Pre-diet |
SA330477 | DS1-28-48 | Pre-diet |
SA330478 | DS1-28-55 | Pre-diet |
SA330479 | DS1-28-37 | Pre-diet |
SA330480 | DS1-28-53 | Pre-diet |
SA330481 | DS1-28-51 | Pre-diet |
SA330482 | DS1-28-40 | Pre-diet |
SA330483 | DS1-28-19 | Pre-diet |
SA330484 | DS1-28-07 | Pre-diet |
SA330485 | DS1-28-04 | Pre-diet |
SA330486 | DS1-28-01 | Pre-diet |
SA330487 | DS1-28-10 | Pre-diet |
SA330488 | DS1-28-13 | Pre-diet |
SA330489 | DS1-28-28 | Pre-diet |
SA330490 | DS1-28-25 | Pre-diet |
SA330491 | DS1-28-16 | Pre-diet |
SA330492 | DS1-28-34 | Pre-diet |
Showing results 1 to 50 of 50 |
Collection:
Collection ID: | CO003152 |
Collection Summary: | Blood samples were collected from consented study subjects and plasma isolated according to standard clinical laboratory protocols. |
Sample Type: | Blood (plasma) |
Treatment:
Treatment ID: | TR003168 |
Treatment Summary: | This study was a clinical trial (NCT02653092) and was approved by the Colorado Multiple Institutional Review Board (COMIRB). All participants provided informed consent. Women aged 18-38 with menstrual cycles 25-35 days in length and no use of reproductive hormones within 3 months of enrollment were eligible for the study. Additional eligibility criteria included: a) no history of chronic disease affecting hormone production, metabolism, or clearance and no use of medications known to interact with reproductive hormones or insulin metabolism; b) normal screening prolactin and TSH; c) normal hemoglobin A1c; d) hemoglobin > 11 g/dl at screening; e) use of reliable non-hormonal contraception throughout the study period. Because the goal was to investigate the effects of a high-fat diet, women with a baseline dietary assessment indicative of >40% calories from fat were excluded, as were women who were unable to comply with the protocol, which involved eating only foods provided by the Colorado Clinical and Translational Sciences Institute’s (CCTSI) Nutrition Services. Because of the restrictions on their ability to consume animal or dairy fats, vegans and lactose intolerant individuals were excluded. Cycle 1 was a baseline cycle; Cycle 2 entailed consumption of the high-fat diet which was continued until frequent blood sampling was completed in the early follicular phase of Cycle 3. Cycle 3 was the immediate post-high-fat-diet cycle and Cycle 4 was a recovery cycle. Participants underwent baseline and end-of-diet assessments of gonadotropin dynamics. A 6-hour frequent blood sampling study was performed to determine endogenous LH and FSH secretion (Time 0-240 minutes) and concluded with a physiologic bolus of 75 ng/kg GnRH to assess pituitary responsiveness (Time 240-360 minutes). Frequent sampling studies for gonadotropin determination were all performed in the early follicular phase of the menstrual cycle (cycle days 2-5). Participants were also seen weekly during the high-fat diet cycle and had a blood draw to assess compliance. High-fat diet protocol. Participants completed a food preference screening survey and a 3-day diet diary, which estimated their daily caloric intake and approximate proportion of daily calories derived from fat. Participants were provided with a customized eucaloric high-fat diet comprised of approximately 48% calories from fat, 33% calories from carbohydrates and 19% calories from protein. Food was portioned into individual meals with snacks and boxed into 3-4 days’ worth at a time. Participants picked up food directly from the Clinical and Translational Research Center; when this was not possible, study staff delivered food to the participant. Urinary ketones were measured at each frequent blood sampling session (Siemens Healthineers, Malvern, PA). During administration of the high-fat diet, blood samples were drawn weekly for metabolomic analysis to determine compliance with the protocol. |
Sample Preparation:
Sampleprep ID: | SP003165 |
Sampleprep Summary: | Lipids from 10 uL of plasma were extracted with 90 uL of cold methanol. Samples were briefly vortexed at room temp then incubated at -20 C for 30 min. Supernatants were clarified by centrifugation (10 min, 10,000 g, 4 degrees C) and transferred to autosampler vials. |
Processing Storage Conditions: | 4℃ |
Extract Storage: | -80℃ |
Combined analysis:
Analysis ID | AN004993 | AN004994 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | Reversed phase | Reversed phase |
Chromatography system | Thermo Vanquish | Thermo Vanquish |
Column | Phenomenex Kinetex C18 (30 x 2.1mm,1.7um) | Phenomenex Kinetex C18 (30 x 2.1mm,1.7um) |
MS Type | ESI | ESI |
MS instrument type | Orbitrap | Orbitrap |
MS instrument name | Thermo Q Exactive Orbitrap | Thermo Q Exactive Orbitrap |
Ion Mode | NEGATIVE | POSITIVE |
Units | peak area | peak area |
Chromatography:
Chromatography ID: | CH003772 |
Chromatography Summary: | Negative C18 |
Instrument Name: | Thermo Vanquish |
Column Name: | Phenomenex Kinetex C18 (30 x 2.1mm,1.7um) |
Column Temperature: | 45 |
Flow Gradient: | 0-3 min 10-95% B at 0.3 mL/min, 3-4.2 min hold at 95% B at 0.3 mL/min, 4.2-4.3 min drop to 10% B at 0.45 mL/min, 4.3-4.9 min hold at 10%B while lowering flow rate to 0.4 mL/min, 4.9-5 min hold at 10%B while lowering flow rate to 0.3 mL/min. |
Flow Rate: | 0.3-0.4 ml/min |
Sample Injection: | 10 uL |
Solvent A: | 75% water/25% acetonitrile; 5 mM ammonium acetate |
Solvent B: | 90% isopropanol/10% acetonitrile; 5 mM ammonium acetate |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH003773 |
Chromatography Summary: | Positive C18 |
Instrument Name: | Thermo Vanquish |
Column Name: | Phenomenex Kinetex C18 (30 x 2.1mm,1.7um) |
Column Temperature: | 45 |
Flow Gradient: | 0-3 min 30-100% B at 0.3 mL/min, 3-4.2 min hold at 100% B at 0.3 mL/min, 4.2-4.3 min 100-30% B at 0.4 mL/min, 4.3-4.9 min hold at 30%B and 0.4 mL/min, 4.9-5 min hold at 30%B while lowering flow rate to 0.3 mL/min |
Flow Rate: | 0.3-0.4 ml/min |
Sample Injection: | 10 uL |
Solvent A: | 75% water/25% acetonitrile; 5 mM ammonium acetate |
Solvent B: | 90% isopropanol/10% acetonitrile; 5 mM ammonium acetate |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS004733 |
Analysis ID: | AN004993 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | The Q Exactive was run independently in positive and negative ion mode, scanning using full MS from 125-1500 m/z at 70,000 resolution and top 10 data-dependent MS2 at 17,500 resolution. Electrospray ionization was achieved with 45 Arb sheath gas, 25 Arb auxiliary gas, and 4 kV spray voltage. Calibration was performed prior to the run using the PierceTM Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific). Run order of samples was randomized and technical replicates were injected after every 4 samples to assess quality control. |
Ion Mode: | NEGATIVE |
MS ID: | MS004734 |
Analysis ID: | AN004994 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | The Q Exactive was run independently in positive and negative ion mode, scanning using full MS from 125-1500 m/z at 70,000 resolution and top 10 data-dependent MS2 at 17,500 resolution. Electrospray ionization was achieved with 45 Arb sheath gas, 25 Arb auxiliary gas, and 4 kV spray voltage. Calibration was performed prior to the run using the PierceTM Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific). Run order of samples was randomized and technical replicates were injected after every 4 samples to assess quality control. |
Ion Mode: | POSITIVE |